Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human immunodeficiency virus type 1 (HIV-1) gp120, Nef, and Tat are three distinct viral proteins that play essential roles in the viral life cycle and pathogenesis (UniProt P04578, P04601, P04608). gp120 is a surface glycoprotein that mediates viral attachment to the host CD4 receptor, a critical first step for entry into T-lymphocytes and macrophages (PubChem). Nef (Negative Regulatory Factor) is an accessory protein that enhances viral infectivity and promotes immune evasion by downregulating cell-surface molecules like CD4 and MHC-I (PubMed). Tat (Trans-Activator of Transcription) is a regulatory protein that drastically increases the efficiency of viral transcription by binding to the TAR element of the viral RNA (PubMed). Because of their individual importance, these proteins are often targeted collectively in the design of therapeutic vaccines and multi-antigen immunotherapies (Gavioli et al., 2008). Such strategies aim to provide a multi-pronged attack that inhibits viral entry, suppresses replication, and restores the host's ability to recognize and eliminate infected cells. The combination of these targets is intended to overcome the limitations of single-antigen approaches, which often fail due to the high mutation rate of the virus.
gp120 inhibitors act as attachment inhibitors by preventing the interaction between the viral envelope and the host CD4 receptor (FDA). Therapeutic vaccines targeting gp120, Nef, and Tat aim to elicit cellular and humoral immune responses to neutralize the virus and destroy infected cells (PubMed).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human immunodeficiency virus type 1 gp120, Nef, and Tat proteins (HIV-1 gp120/Nef/Tat).